AFRIN NO DRIP ORIGINAL OTC
Generic Name and Formulations:
Oxymetazoline HCl 0.05%; pump mist.
Merck & Co., Inc.
Indications for AFRIN NO DRIP ORIGINAL:
Adults and Children:
<6yrs: individualize. ≥6yrs: 2–3 sprays in each nostril not more than every 10–12 hours. Max 2 doses/day.
Use >3 days; may worsen nasal congestion.
Heart disease. Hypertension. Thyroid disease. Diabetes. Urinary retention. Enlarged prostate. Pregnancy. Nursing mothers.
Local effects (eg, burning, stinging, sneezing, increased nasal discharge).
Original nasal spray—30mL; No Drip Original, Severe Congestion, Extra Moisturizing, Sinus—15mL
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally